Harbin Gloria, founded in March. 2000, is a high-techbiopharmaceuticalcorporate groupenterprise,basing on pharmaceutical business and dedicated to massive health industry, involvingcoveringfrom R&D, manufacturing to , commercializationrelated to of the whole value chain in the healthcare industry.

Gloria was listed on Shenzhen Stock Exchange (Stock code: 002437) in 2010.Insisting on "Product Leadership" strategy, we expanded our product portfolio by M&A, collaboration, overseas in-licensing and self R&D, starting from single therapeutic areanow into a diversified portfolio in cardiovascular, musculoskeletal and nutritional areas.

We made our best efforts to build up an integrated industry aiming for the highest standards. Quality at Gloria is a mindset that drives us to strive for excellence, from R&D to production, from distribution to marketing. We set up multiple manufacturing facilities in Harbin, Baoding, Guangzhou, Datong and Qidong, as well as outstanding sales and distribution system all over the nation.

Gloria consistently pushes innovation forward to international standard, focuses on "product, mechanism, talent", proactively optimizes resources allocation and plans our pipeline in novel biopharmaceuticals and chronic diseases management.

We are driven by a strong sense of value "more splendid because of you", laying emphasis on sharing, enthusiasm in public service and commitment to social responsibility. In Gloria, we share together not only fortunes but spiritual communication and resonance, pains and joys of growing. There's no individual success or honor, but only a long journey together toward the same direction.

We are driven by a strong sense of value "more splendid because of you", laying emphasis on sharing, enthusiasm in public service and commitment to social responsibility. In Gloria, we share together not only fortunes but spiritual communication and resonance, pains and joys of growing. There's no individual success or honor, but only a long journey together toward the same direction.

With a steady and robust development, Gloria continuously reaches to a new stage and becomes to an integrated pharmaceutical company, ranking on the top in the industry. In 2016, total revenue was RMB 2.98 billion, total assets RMB 8.67 billion and over 3,000 employees. The distribution network spreads into 31 provinces, more than 6,000 hospitals and 100,000 pharmacies. Gloria has been granted many awards from industry, association and authorities.

In the future, Gloria will develop and further expand with full efforts to public health service, carrying on our mission that driven by products and talents, Gloria is going to be a leading internationalized Chinese pharmaceutical company to create values and provide services to public.